线粒体蛋白酶ClpP是多发性骨髓瘤的代谢脆弱点与免疫原性触发因素
研究发现线粒体蛋白酶ClpP在多发性骨髓瘤(MM)恶性浆细胞中表达高于正常或癌前细胞,MM细胞系在人类癌症中ClpP表达排名第一。体外和体内实验显示MM细胞对ClpP抑制高度脆弱,其依赖性与氧化磷酸化监测功能无关,而是通过控制鸟氨酸氨基转移酶维持多胺合成。ClpP沉默还激活cGAS依赖的I型干扰素反应,重塑骨髓免疫环境,扩展产生IFN-γ的CD4+和CD8+ T细胞及CD4+记忆T细胞。
要点
- ClpP mRNA在骨髓纯化恶性浆细胞中高于正常或癌前细胞,MM细胞系在人类癌症中ClpP表达排名第一。
- MM细胞对ClpP抑制在体外和体内高度脆弱,该依赖性不由氧化磷酸化监测活性解释。
- ClpP通过控制鸟氨酸氨基转移酶丰度维持多胺的胞质生物合成,多胺对MM细胞至关重要。
核心结论
- ClpP是MM细胞新发现的依赖因子,其抑制既发挥细胞内在毒性又触发抗肿瘤免疫。
- 研究提出一种新的免疫原性化疗框架,可能与骨髓瘤相关。
研究设计与样本
- 研究检测了骨髓纯化恶性浆细胞与正常或癌前对应细胞的ClpP mRNA水平,并比较了MM细胞系在人类癌症中的ClpP表达排名。
- 体外和体内实验评估了MM细胞对ClpP抑制的脆弱性。
- 采用蛋白质组学发现蛋白水解靶标、代谢组学和代谢示踪鉴定ClpP对鸟氨酸氨基转移酶的调控。
- 转录组学和靶向验证检测ClpP沉默MM细胞中cGAS依赖的I型干扰素反应。
- 在免疫健全小鼠体内评估ClpP沉默对骨髓免疫环境的影响。
主要发现
- ClpP mRNA在骨髓纯化恶性浆细胞中高于正常或癌前对应细胞,MM细胞系在人类癌症中ClpP表达排名第一。
- 人MM细胞在体外和体内对ClpP抑制高度脆弱。
- MM细胞对ClpP的依赖不由其公认的氧化磷酸化监测活性解释。
- ClpP控制鸟氨酸氨基转移酶丰度以维持多胺的胞质生物合成。
- ClpP沉默的MM细胞激活cGAS依赖的I型干扰素反应,其上清增强树突状细胞活化和刺激T细胞产生IFN-γ的能力。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Orchestrating key homeostatic functions, mitochondria likely entail cancer vulnerabilities. Moreover, because of their bacterial ancestry, they can release potent immunogenic signals. In this study, we showed that the mitochondrial protease caseinolytic peptidase P (ClpP) is both a cell-intrinsic metabolic vulnerability and an actionable immunogenic trigger in multiple myeloma (MM). We found that ClpP messenger RNA is higher in bone marrow (BM)-purified malignant plasma cells than in normal or premalignant counterparts and that MM lines rank first in ClpP expression among human cancers. Moreover, we demonstrated that human MM cells are highly vulnerable to ClpP inhibition in vitro and in vivo. Surprisingly, MM cell dependence on ClpP was not accounted for by its acknowledged oxidative phosphorylation surveillance activity. Proteomic discovery of proteolytic targets, metabolomics, and metabolic tracing identified a critical control exerted by ClpP on ornithine aminotransferase abundance to sustain cytosolic biosynthesis of polyamines, which are essential for MM cells. Transcriptomics and targeted validation also revealed the activation of a cyclic GMP-AMP synthase (cGAS)-dependent type I interferon (IFN) response in ClpP-silenced MM cells, whose supernatants boosted dendritic cell activation and ability to stimulate IFN-γ production by T cells. In vivo, ClpP silencing reshaped the BM immune environment in immunocompetent mice by significantly expanding IFN-γ-producing CD4+ and CD8+ T cells and CD4+ T memory cells, while containing exhausted CD4+ T cells and myeloid-derived suppressor cells. Thus, ClpP is a newly identified addiction of MM cells whose inhibition not only exerts cell-intrinsic toxicity but also triggers otherwise indolent antitumoral immunity. Our findings yield a novel immunogenic chemotherapeutic framework with potential relevance to myeloma.
引用
- Perini T, Zordan P, Del Pizzo R, et al. The mitochondrial protease ClpP is a metabolic vulnerability and an immunogenic trigger against multiple myeloma. Blood. 2025. PMID: 40300074. doi:10.1182/blood.2024026340
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。